Skip to main content
Premium Trial:

Request an Annual Quote

Lynx CEO Resigns As Company Proceeds With Solexa Merger

NEW YORK, Nov. 22 (GenomeWeb News) - Kevin Corcoran has resigned as CEO, president, and director of Lynx Therapeutics "to pursue another business opportunity," Lynx said last week.

 

He will be replaced by Mary Schramke, Lynx's vice president of product development, who will become acting CEO on Dec. 15. She will lead the company as it proceeds with its merger with Solexa. Schramke holds a PhD in microbiology from LouisianaStateUniversity, Baton Rouge, and an MBA from JohnF.KennedyUniversity.

 

Corcoran spent nine years at Lynx, working in various managerial positions, and was responsible for the company's short read DNA sequencing technology.

Lynx and Solexa are scheduled to merge during the first quarter of 2005. The companies had originally planned to tie the knot during the fourth quarer of 2004.

Read the following most-recent GenomeWeb News articles about Lynx and its impending merger with Solexa:

 

Lynx Reports Lower Q3 Revenues Amid Flat Expenses; Stock Rises and Falls  (11/15/04)

Lynx, In Worse Shape Than Previously Thought, Gets More Cash From Solexa (10/29/04)

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.